Baidu
map

JCO:肥胖和乳腺癌预后证据,挑战与机遇

2016-12-01 MedSci MedSci原创

这项综述整理总结了肥胖和乳腺癌预后之间的关联性证据。选取超重或肥胖与乳腺癌生存结果,总生存,乳腺癌亚型,乳腺癌治疗方案,生物学机制或可能的影响因素相关联的文章,从中总结规律,从而提供更好的临床管理建议。

这项综述整理总结了肥胖和乳腺癌预后之间的关联性证据。选取超重或肥胖与乳腺癌生存结果,总生存,乳腺癌亚型,乳腺癌治疗方案,生物学机制或可能的影响因素相关联的文章,从中总结规律,从而提供更好的临床管理建议。

分析结果显示,肥胖可增加35%~40%的乳腺癌复发死亡风险,从而导致肥胖人群的预后生存较差。尤其是对于雌激素受体阳性的乳腺癌患者更甚。但针对三阴性乳腺癌及Her-2受体阳性的肥胖乳腺癌患者则相关证据不足。已有证据证明,这种关联性与人体内一系列的生物学机制有关。减肥或者是采取健康生活方式干预,以及二甲双胍或其他的肥胖靶向治疗,有望提高患者的生存率,不过还需要大量的实验数据证实。

分析结果可以得出结论,肥胖患者的乳腺癌预后较差。进一步的研究这种效应的生物学机制可以为改善肥胖乳腺癌患者的诊断,治疗和生存提供重要机遇。

原始出处:Jiralerspong S, Goodwin PJ. Obesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities. Journal of Clinical Oncology 2016;34:4203-16.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2017-07-21 lidong40
  2. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2017-02-02 墨尔

    或许可以尝试二甲双胍吗?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2016-12-09 ys2323

    减肥减肥!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2016-12-07 虈亣靌

    讲的很好,点个赞

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2016-12-02 杨帆7792

    英缺是挺

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1891321, encodeId=62341891321c1, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 21 21:01:00 CST 2017, time=2017-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=173825, encodeId=c1a51e38257e, content=或许可以尝试二甲双胍吗?, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ee471989203, createdName=墨尔, createdTime=Thu Feb 02 16:02:42 CST 2017, time=2017-02-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=161508, encodeId=3afc1615084b, content=减肥减肥!, beContent=null, objectType=article, channel=null, level=null, likeNumber=135, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 09 19:47:58 CST 2016, time=2016-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=160955, encodeId=94d616095535, content=讲的很好,点个赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Wed Dec 07 13:48:39 CST 2016, time=2016-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159715, encodeId=49cb159e1565, content=英缺是挺, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/11/19/9bc45f4ae162bd654210831f4e7ea3d0.jpg, createdBy=bbf11609910, createdName=杨帆7792, createdTime=Fri Dec 02 16:20:54 CST 2016, time=2016-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=159644, encodeId=04bf159644cf, content=机遇挑战并存, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Fri Dec 02 10:43:41 CST 2016, time=2016-12-02, status=1, ipAttribution=)]
    2016-12-02 oo902

    机遇挑战并存

    0

相关资讯

青少年儿童喝太多含糖饮料诱发肥胖增加患癌风险

英国癌症研究会近日发布的一项研究显示,由于大量饮用含糖饮料,英国的儿童和青少年都存在糖分摄入过量现象,给他们的健康带来较大潜在风险。 英国公共卫生部门给出的建议是:4岁至6岁儿童每天摄入的额外糖分应该不超过19克,7岁至10岁不超过24克,11岁以上不超过30克。 英国癌症研究会研究人员利用英国“2015年国家饮食和营养调查”的数据,详细分析了不同年龄段儿童和青少年的糖分摄入量,发

2016AHA科学声明:慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险发布

2016年10月,美国心脏协会(AHA)发布了关于慢性心衰合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理以及分摊风险的科学声明。高血压,糖尿病,肥胖,高脂血症和代谢综合征是心衰患者常见的合并症并且影响临床结局。本文的主要目的是总结了分摊风险的相关数据并对心衰患者合并高血压,肥胖,糖尿病,高脂血症和代谢综合征的管理提供指导。全文获取:下载地址:指南下载 (需要扣积分2分, 

中国山东限盐项目:胖人更应限盐,也应重视补充饮食钾

清华大学北京清华长庚医院张啸飞和中国疾控中心慢病中心马吉祥等对山东省-原卫生部联合减盐防控高血压项目(SMASH)人群进行的研究提示,对于超重和肥胖者,高钠低钾饮食对血压的影响更大。 张啸飞表示,钠钾比例无论在超重人群还是全部人群,与 血压都呈正相关关系,与钾呈负相关关系。要关注膳食摄入盐水平,即摄入钠水平,更需要关心钾水平、钠钾比例水平,尤其是肥胖人群。研究在一个来自山东的人群中开展,

Cell rep:胖子有可能比瘦子更健康吗?

肥胖和代谢问题之间到底存在怎样的联系,仍有待探索。 一个最新的研究发现,来自肥胖人群和健康人群的脂肪细胞在代谢方面存在显著差异,尽管这一差异对于健康有怎样的影响现在还不明确。 为什么要研究这个? 肥胖与糖尿病和心脏病有着密切的关系。但是在过去的15年里,有证据表明,一部分肥胖人群的代谢是正常的,这意味着他们这种肥胖没有伴随着胰岛素抵抗(即正常胰岛素浓度无法让细胞产生足

Clin Endocrinol:尿双酚A水平越高,越容易肥胖!

研究数据显示,生育期的韩国女性,其肥胖、胰岛素抵抗和代谢紊乱与高尿双酚A水平有关联。 来自韩国梨花女子大学医学院的内分泌代谢内博士和同事们对296名生育期(平均年龄36岁)的健康女性进行了研究,调查内分泌干扰物质与胰岛素抵抗和肥胖之间的联系。 使用高效液相色谱-串联质谱法测定尿中双酚A(BPA)、MEHHP、MEOHP和MnBP水平。 分析结果显示,BMI (P < .01

病态肥胖者还是先接受减肥手术,再进行关节置换术吧

美国髋膝关节外科医师协会年会上有数据显示,病态肥胖患者在全关节置换术前进行减肥手术,可减少术前合并症负担和人工关节置换术时的并发症负担。 Ashley E. Levack博士说:“我们都知道美国的肥胖正在流行,更年轻和体重更重的患者需要人工关节置换术[TJA],这些患者的疾病和并发症负担也很高,尤其是BMI超过40的患者。” “不过,肥胖是一个潜在可改变的危险因素,比如TJA之前进行减

Baidu
map
Baidu
map
Baidu
map